Richard Simon, NCI’s visionary biostatistician, dies at 80

Moffitt receives $22.4M grant to advance research and clinical trials for leptomeningeal disease

Researchers at Moffitt Cancer Center have been awarded a $22.4 million grant from the U.S. Department of War to lead studies and clinical trials for leptomeningeal disease, a devastating complication of breast and other cancers that spreads to the coverings of the brain and spinal cord.

October 10, 2025

Vol.51 No.37

Clinical Roundup

Datroway improves OS as first-line therapy in metastatic TNBC, phase III trial shows

Positive high-level results from the Tropion-Breast02 phase III trial showed Datroway (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival compared to investigator’s choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not an option.

October 10, 2025

Vol.51 No.37

Clinical Roundup

Five-treatment radiation regimen poised to become standard of care, phase III data show

Men with intermediate-risk prostate cancer can receive a complete course of radiation in just five treatments—rather than the typical 20 to 28—while maintaining excellent cancer control and improving quality of life, according to results of an international phase III trial conducted by Rodney J. Ellis.

October 10, 2025

Vol.51 No.37

Clinical Roundup

Alliance trial aims to improve outcomes in metastatic prostate cancer

The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial—a large-scale, phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend survival for men living with advanced prostate cancer.

October 10, 2025

Vol.51 No.37

NCI

Anthony Letai sworn in as 18th NCI director

Anthony G. Letai, accompanied by his wife Jean, was sworn in by HHS Secretary Kennedy as the 18th NCI Director on Sept. 29.Anthony G. Letai, a physician-scientist at Harvard Medical School and Dana-Farber Cancer Institute, has been officially named the 18th director of the National Cancer Institute.

October 03, 2025

Vol.51 No.36

By Claire Marie Porter

Capitol Hill

U.S. government shuts down
Impact on NCI uncertain as administration threatens more RIFs

On Oct. 1, for the first time in six years, the U.S. government shut down after Congress was unable to reach a deal to fund federal agencies for Fiscal Year 2026.

October 03, 2025

Vol.51 No.36

By Claire Marie Porter

Richard Simon, NCI’s visionary biostatistician, dies at 80

YOU MAY BE INTERESTED IN

Moffitt receives $22.4M grant to advance research and clinical trials for leptomeningeal disease

Datroway improves OS as first-line therapy in metastatic TNBC, phase III trial shows

Five-treatment radiation regimen poised to become standard of care, phase III data show

Alliance trial aims to improve outcomes in metastatic prostate cancer

Anthony Letai sworn in as 18th NCI director

U.S. government shuts down
Impact on NCI uncertain as administration threatens more RIFs

Renew today!

Subscriber content

Never miss an issue!

Login

Richard Simon, NCI’s visionary biostatistician, dies at 80

YOU MAY BE INTERESTED IN

Moffitt receives $22.4M grant to advance research and clinical trials for leptomeningeal disease

Datroway improves OS as first-line therapy in metastatic TNBC, phase III trial shows

Five-treatment radiation regimen poised to become standard of care, phase III data show

Alliance trial aims to improve outcomes in metastatic prostate cancer

Anthony Letai sworn in as 18th NCI director

U.S. government shuts downImpact on NCI uncertain as administration threatens more RIFs

Never miss an issue!

Login

U.S. government shuts down
Impact on NCI uncertain as administration threatens more RIFs